Todd A Fehniger MD PhD

Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 314-454-8304
Fax+1 314-454-5902

Dr. Fehniger is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fehniger's full profile Already have an account?

Summary

Dr. Todd Fehniger is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from The Ohio State University College of Medicine and has been in practice 15 years. He specializes and is board certified in medical oncology and is experienced in blood cancers (leukemia, lymphoma, and related diseases), hematopoietic cell transplantation (bone marrow transplantation, cellular therapy (CAR T cells).

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2004 - 2008
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2002 - 2004
Ohio State University College of MedicineClass of 2002

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MO State Medical License 2004 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2017
CMS Meaningful Use Stage 1 Certification Follow My Health, Jardogs, 2013-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Modular), Allscripts, 2013-2017

Clinical Trials

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2007 Sep 06
COMPLETED
PHASE2
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma Start of enrollment: 2011 Apr 28
COMPLETED
PHASE1
CNDO-109-AANK for AML in First Complete Remission (CR1)
UNKNOWN
PHASE1, PHASE2

Publications & Presentations

PubMed

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Ryan C Lynch, Christina Poh, Mazyar Shadman, Brian G Till, Mengyang Di
Journal of Clinical Oncology. 2026-08-14
NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.
Omar H Butt, Kartik Singhal, Jingqin Luo, Michael P Rettig, Jennifer A Foltz
Clinical Cancer Research. 2026-07-01
Automating neoantigen selection for personalized cancer vaccine design.
Jennie X Yao, Kartik Singhal, Susanna Kiwala, Evelyn Schmidt, S Peter Goedegebuure
Medrxiv. 2026-07-01

Journal Articles

A Deep Learning Approach to Automate Refinement of Somatic Variant Calling from Cancer Sequencing Data
Ravindra Uppaluri, Gavin P Dunn, Ramaswamy Govindan, S Joshua Swamidass, Todd A Fehniger, Nature
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after...
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

The Making of Memory
60th American Society of Hematology Annual Meeting - 12/1/2018
Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

WashU Startups Attract Record-Setting $1.7 Billion in Private-Sector Investment Over Past YearJanuary 6th, 2026
$10.8 Million Grant Supports Cutting-Edge Leukemia ResearchDecember 16th, 2024
World Leaders in Ending Blood CancerNovember 14th, 2024